{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-067682","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.850611+00:00","generated_at":"2026-06-22T21:45:22.454728+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rafael Holdings full-year net loss $122.8M on $114.2M impairment; Q4 loss narrows to $4.6M","bullets":["Q4 net loss from continuing ops $4.6M ($0.24/share) vs $12.2M ($0.75) YoY; revenue $0.07M.","Full-year net loss $122.8M ($6.22/share) includes $114.2M impairment of Cornerstone investment and receivables.","Cash & marketable securities $63.2M at July 31, plus $33M net from real estate sale in Aug 2022.","R&D expenses rose to $8.7M from $4.9M, reflecting early-stage pipeline spending.","G&A held at $17.0M, includes $5.9M severance; prior year had $6.6M stock-based comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-067682","json":"https://secwatch.observer/filing/0001213900-22-067682.json","markdown":"https://secwatch.observer/filing/0001213900-22-067682.md","text":"https://secwatch.observer/filing/0001213900-22-067682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022067682/0001213900-22-067682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022067682/ea167666-8k_rafaelhold.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:45:22.454728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a86b1efc635b657e21187d3f6a69b224278e6d76","claim":"Rafael Holdings, Inc. reported the three months ended July 31, 2022 results: revenue $0.07 million, net income $4.6 million, EPS $0.24 per share.","evidence_excerpt":"For the three months ended July 31, 2022, we incurred a net loss from continuing operations of $4.6 million, or $0.24 per share, which includes $1.2 million in non-cash stock-based compensation expense. For the same period in the prior year, we incurred a net loss from continuing operations of $12.2 million, or $0.75 per share, which included $5.6 million in non-cash stock-based compensation expense. Our revenues from continuing operations for the three months ended July 31, 2022, amounted to $0.07 million, compared to revenues of $0.19 million for the same period in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022067682/0001213900-22-067682-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended July 31, 2022"},{"label":"Revenue","value":"$0.07 million"},{"label":"Net income","value":"$4.6 million"},{"label":"EPS","value":"$0.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ed9f41775d501ed0c0f33972cb737f03544c6269","claim":"Rafael Holdings, Inc. reported the twelve months ended July 31, 2022 results: revenue $0.4 million, net income $122.8 million, EPS $6.22 per share.","evidence_excerpt":"For the twelve months ended July 31, 2022, we incurred a net loss from continuing operations of $122.8 million or $6.22 per share, w hich includes an impairment of cost method investment and losses from loans and receivables from Cornerstone Pharmaceuticals, Inc. (formerly Rafael Pharmaceuticals, Inc.) totaling $114.2 million. For the same period in the prior year, we incurred a net loss from continuing operations of $22.8 million, or $1.38 per share which included $6.6 million in non-cash stock-based compensation expense. Our revenues from continuing operations for the twelve months ended July 31, 2022, amounted to $0.4 million compared to $0.8 million in the same period in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022067682/0001213900-22-067682-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended July 31, 2022"},{"label":"Revenue","value":"$0.4 million"},{"label":"Net income","value":"$122.8 million"},{"label":"EPS","value":"$6.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}